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Background: Excessive circular fatty acid, particlarly saturated fatty acid, can result in insulin resistance in skeletal
muscle, but other adverse effects of fatty acid accumulation in myocytes remain unclear.
Methods: Differentiated C2C12 myotubes were used. The effects of palmitate on cell viability, glucose uptake, gene
expression and myotube loss were evaluated by MTT assay, 2NBDG uptake, qRT-PCR, Western Blot and crystal
staining-based myotube counting, respectively. In some expreiments, oleate was administrated, or the inhibitors of
signaling pathways were applied.
Results: Palmitate-induced cellular insulin resistance was clarified by the reduced Akt phosphorylation, glucose
uptake and Glut4 expression. Palmitate-caused myotube loss was clearly observed under microscope and proved
by myotube counting and expression analysis of myotube marker genes. Moreover, palmitate-induced
transcriptional suppression of three health benefit myokine genes (FNDC5, CTRP15 and FGF21) was found, and the
different involvement of p38 and PI3K in the transcription of these genes was noticed.
Conclusions: Palmitate-induced insulin resistance accompanys myotube loss and the impaired expression of
FNDC5, CTRP15 and FGF21genes in C2C12 myotubes. These results provide novel evidence indicating the negative
role of high concentration of palmitate in myotubes.
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Insulin resistance is one of the major characteristics of
type 2 diabetes mellitus (T2D) and also occurs with obes-
ity, hypertension and cardiovascular disease [1,2]. Exces-
sive high level plasma free fatty acids (FFA) is known to
associate with insulin resistance in diabetic patients and
nondiabetic subjects [3,4]. Correspondingly, an impair-
ment of glucose use and insulin sensitivity has been ob-
served in experimental studies with high concentration
FFA administration. As skeletal muscle accounts for more
than 70% of insulin-stimulated glucose consumption, its* Correspondence: hengyix@scu.edu.cn
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reproduction in any medium, provided the orstatus can obviously affect whole body plasma glucose
concentration and insulin sensitivity [2]. In fact, high con-
centration of FFA, particularly the most abundant dietary
saturated fatty acid palmitate, can directly impair insulin
signaling in skeletal muscle cells [5,6].
The mechanism underlying palmitate-induced insulin
resistance remains unclear, with one hypothesis indicat-
ing that palmitate acts through protein kinase C (PKC)
to negatively regulate the ability of IRS-1 to activate
PI3K-Akt pathway [7,8]. Meanwhile, our understanding
about the consequences of palmitate-induced insulin re-
sistance in myotubes is limited. The most known one is
decreased glucose uptake [9,10].
Myotube formation is a morphologic and functional
feature of skeletal muscle. It shapes upon a homeostasis
between myofiber synthesis and proteolysis [11,12]. Asd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ant myofiber components and muscle creatine kinase
(MCK) is a muscle specific ATPase necessary for
myofiber assembly and contraction [11]. Moreover, A
study demonstrates that palmitate has negative effect on
the myotube size and morphology in differentiated
C2C12 cells [13]. Moreover, it has found that myotube
atrophy or myotube loss is a common syndrome of late
T2D and other catabolic diseases [14-16]. But, if and
how the high level of fatty acids affects myotube homeo-
stasis is still an open question.
Diverse myokines are produced by muscle cells [17].
Some of them, such as irisin (N-terminal portion of
FNDC5 pro-protein), CTRP15 and fibroblast growth
factor-21 (FGF21), have attracted an increasing attention
in recent years because of their potential beneficial roles
in metabolic homeostasis and protecting human body
from the damages of metabolic diseases [18-20]. How-
ever, little is known about the connection between high
fatty acids and the expression of myokine genes in
C2C12 myotubes.
The purpose of this study, therefore, is to investigate
the influence of palmitate in muscle fiber composition
and the expression of FNDC5, CTRP15 and FGF21





cose (2NBDG) was from Invitrogen, palmitate from
Sigma, oleate from Alligator Reagent, fatty free BSA from
MP Biomedicals, LY294002 and SB203580 and MG132
from Calbiochem.
Cell culture and differentiation
Mouse C2C12 myoblasts (American Type Culture Col-
lection) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS. C2C12
myotubes were obtained by culturing myoblasts in
DMEM containing 2% heat-inactivated horse serum for
at least 4 days.
Fatty acids preparation and cell treatment
Palmitate was prepared as described previously [21].
Briefly, palmitate was dissolved in 0.1M NaOH by
heating at 70°C. After filtration, the solution was then
diluted with 10% fatty free BSA and stored at −20°C.
Oleate was dissolved in PBS by heating at 55°C, and di-
luted with 10% fatty free BSA and stored at −20°C.
Palmitate and oleate treatments were performed with
the concentrations indicated in figure legends for gener-
ally 24 hours as described previously [22]. In all experi-
ments, 2 hours before the treatment of fatty acids,cultural medium were changed to serum free DMEM.
For protein phosphorylation detection, 100 nM insulin
was added for 15 min before cell lysates harvest. In some
experiments, cells were pretreated with LY294002,
SB203580, MG132 or vehicle for 1 hour before stimulat-
ing with palmitate.
Cell viability assay
Cell viability was measured using the MTT (3-(4, 5)-
dimethylthiahiazo (−z-y1)-3, 5-diphenytetrazoliumromid)
assay, based on the MTT conversion into formazan crys-
tals using mitochondrial dehydrogenases. Briefly, C2C12
cells were plated at a density of 2×104 cells/well in a 96-
well plate. After differentiation and palmitate treatment
for 24 hours, 15 μl of 5 mg/ml MTT was added to each
well. After 4 hours incubation at 37°C, this solution was
removed carefully and the produced formazan was solubi-
lized in 150 μl dimethyl sulfoxide (DMSO). The absorb-
ance was measured at 490 nm using a microplate reader
(Bio-Rad).
Measurement of 2NBDG uptake
After 2 hours incubation in no glucose DMEM, myo-
tubes were incubated with or without 100 nM insulin
for another 1 hour. Next, myotubes were transferred to
fresh no glucose DMEM medium supplemented with
80 uM fluorescent deoxyglucose 2NBDG for 30 min. After
three times washed by PBS, myotubes were lysed by 0.5%
TritonX-100 and the fluorescence intensity was recorded
using a microplate reader (Thermo) at excitation and
emission wavelengths of 485 and 538 nm, respectively.
Crystal violet staining
Cells were fixed for 10 min with 4% paraformaldehyde
(PFA), then stained with 1% crystal violet for 5min, and
washed two times with water.
Myotube counting
After crystal violet staining, nine visual fields for each
treatment were photographed under a microscope. The
number of myotubes in these photographs was deter-
mined following counting. Myotubes were identified as
obviously bigger or longer morphology than undifferen-
tiated C2C12 myoblasts.
Real time-PCR
Total RNA extraction, reverse transcription reaction and
quantitative real-time PCR assays were performed as de-
scribed previously [23]. Briefly, total RNA was extracted
using RNA iso plus reagent (TaKaRa). cDNA was pre-
pared using TransScript II First-Strand cDNA Synthesis
SuperMix kit (Transgen). Quantitative real-time PCR
(qRT-PCR) analysis was performed using a TaqMan
Probe Mix (Transgen) using a Bio-Rad IQ5 detection
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mRNA levels relative to those of 18S, and normalized to
the mean value of samples from control.
Western blot
Cell lysates were subjected to SDS-PAGE and western
blot analysis [23]. Briefly, cells were lysed with protein
lysis buffer followed by heat denaturation. 20ug of whole
cell proteins were applied to SDS-PAGE. After electro-
phoresis, the proteins were transferred to PVDF mem-
branes, and blocked in the TBST buffer containing 5%
nonfat dry milk for 1 hour at room temperature. The
membranes were probed with the following different
primary antibodies: anti-phosphorylated-Akt1 (Ser473)
(Epitomics), anti-FNDC5 (Abcam), anti-phosphorylated-
p70S6K (Ser371) (Cell signaling technology), anti-α-actin
(ZSGB-BIO), anti-GAPDH (ZSGB-BIO) and anti-β-actin
(ZSGB-BIO), and then washed and incubated with
peroxidase-conjugated secondary antibody and finally
visualized using Chemiluminescent HRP Substrate reagent
(Millipore MA, USA) using an ECL detection system
(Amersham Biosciences).
Statistical analysis
Data, represented as the means ± SEM, were analyzed
by the Student’s t-test for comparison of two groups or
one-way ANOVA for multiple comparisons using the
SPSS 17 software (SPSS Inc. Chicago, Illinois) to deter-
mine any significant differences. p<0.05 was considered
significant.
Results
Palmitate induced insulin resistance in C2C12 myotubes
The inhibitory effect of chronic palmitate treatment on
insulin/PI3K signaling pathway in myotubes was tested
at first. The result of MTT assay showed that lower than
0.6 mM of palmitate did not significantly suppress theTable 1 Primers for RT-PCR












18S TTGACGGAAGGGCACCACCAGcell viability of C2C12 myotubes (Figure 1A). So, we
chose 0.6 mM and lower concentrations of palmitate for
next experiments. As shown, 0.2 to 0.6 mM of palmitate
suppressed insulin-stimulated phosphorylation of Akt1
(Ser473) and p70S6K (Ser371) (Figure 1B). Correspond-
ingly, palmitate inhibited insulin-stimulated 2NBDG up-
take in a dose-dependent manner, i.e. 0.2 mM, 0.4 mM,
0.6 mM of palmitate inhibited 2NBDG uptake by 13.7%,
23.9%, 26.5%, respectively (Figure 1C). These concentra-
tions of palmitate also decreased the transcription of
glucose transporter 4 (Glut4) gene by 42%, 72%, 78%, re-
spectively (Figure 1D). Taking together, our data suggest
that 0.2 to 0.6 mM of palmitate reduce the insulin sensi-
tivity of C2C12 myotubes.
Palmitate, but not oleate, induced myotube loss in C2C12
myotubes
Except insulin resistance, we noticed that palmitate had
an apparent effect on morphous of myotubes (Figure 2A).
We found that myocytes treated with 0.2 mM, 0.4 mM
and 0.6 mM palmitate caused a significantly decrease in
the number of myotubes by 14%, 41%, 49%, respectively
(Figure 2B). In addition, the transcriptions of four
marker genes relevant to muscle differentiation and
myofiber composition, which are myogenin, MHC1, 2b
and muscle creatine kinase (MCK), were suppressed by
palmitate at different levels (Figure 2C). In the contrary,
up to 0.6 mM concentrations of oleate, an unsatuated
fatty acid, did not induce myotube loss, whenever it was
used alone or together with palmitate (Figure 2D and
unpresented data). These results demonstrate that
palmitate induced myotube loss in C2C12 myotubes.
Palmitate-induced myotube loss could not be duplicated
by the blockage of PI3K pathway and p38 pathway
PI3K- and p38-mediated pathways are known to partici-













Figure 1 Palmitate induced insulin resistance in C2C12 myotubes. Myotubes were treated with indicated concentrations of palmitate for
24 hours. (A) Cell viability of C2C12 myotubes was evaluated by MTT assay. (B) Cells were stimulated with insulin (100 nM) for 15 min before
harvest. Phosphorylated Akt1 (Ser473) and phosphorylated p70S6K (Ser371) were immunoprobed in western blot. GAPDH was detected as
internal control. (C) 2NBDG uptake was carried out as described in Materials and Methods and intracellular fluorescence intensity was measured
by a microplate reader. *p<0.05 vs. control stimulation with insulin. (D) The transcription of Glut4 gene was measured by qRT-PCR. The values
were monitored by 18S and expressed as mean±SEM (n=3). *p<0.05 vs. control (CTL). PA, palmitate.
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palmitate-induced myotube loss. Unexpectedly, neither
LY294002 (PI3K inhibitor) nor SB203580 (p38MAPK
inhibitor) induced significant myotube loss in C2C12
myocytes like palmitate (Figure 3). These data demon-
strate that the blockage of PI3K and p38 pathways by
chemical inhibitors can not mimic the palmitate-induced
myotube loss.
Palmitate-induced myotube loss was associated with
protein degradation
To know whether palmitate-induced myotube loss was as-
sociated with increased proteolysis, we measured the tran-
scription of two marker genes of proteasome-mediated
protein degradation pathway, Atrogin1 and MuRF1 [24].
As shown, palmitate slightly increased the expression of
Atrogin1 and MuRF1 genes (Figure 4A), but reduced the
protein levels of α-actin and β-actin (Figure 4B). To know
whether palmitate-induced myotube loss was proteasome-
dependent, myotubes were pretreated with MG132 (prote-
asome inhibitor) prior to palmitate. As the results, 10 uM
of MG132 for 1h did not prevent the myotube loss in-
duced by palmitate, but showed apparent cytotoxicity and
aggravated myotube loss (Figure 4C). Actually, we tested a
wild range concentrations of MG132 for knowing its rolein palmitate-induced myotube loss, In 1 uM to 5 uM of
concentrations, MG132 was nontoxic but no impact on
myotube morphology, either used alone or together with
palmitate (data not shown); in 10 to 50 uM, MG132 was
also nontoxic when used alone, but showed increasing
toxicity with corresponding extents of cell death when
used together with palmitate (data not shown). These re-
sults suggest that palmitate-induced myotube loss is asso-
ciated with protein degradation, but the involvement of
proteasome in this phenomenon need to be confirmed.
Palmitate suppressed the expression of three health
benefit myokine genes but promoted that of IL6 gene
FNDC5, CTRP15 and FGF21 show health benefit roles in
metabolism interference [18-20]. Up to now, the expres-
sion regulation about these myokines is largely unknown.
To explore the connection between insulin resistance and
the expression of these myokine genes, qRT-PCR assay
was utilized. Palmitate suppressed the transcription of
FNDC5 and CTRP15 genes (Figure 5A,B). However,
palmitate showed a bidirectional influence to the tran-
scription of FGF21 gene, being inhibitory at 0.2 mM con-
centration but stimulative at 0.4 mM and 0.6 mM
concentration (Figure 5C). Oppositely, the expression of
IL6 gene, encoding a pro-inflammatory cytokine which is
Figure 2 Palmitate induced C2C12 myotube loss. Myotubes were treated with palmitate or/and oleate for 24 hours. (A) Photographs were
taken before (light) or after (crystal violet staining) 1% crystal violet staining under a phase contrast microscope; (B) The number of myotubes per
photograph was counted after crystal violet staining (n=9). (C) The transcription of myogenin, MHC1, MHC2b and MCK genes was measured by
qRT-PCR. The values were monitored by 18S and expressed as mean±SEM (n=3). (D) Photographs were taken like (A), and the number of
myotubes per photograph was counted. *p<0.05, **p<0.01 vs. CTL. PA, palmitate; OL, oleate; CTL, control.
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tate in a dose-dependent manner (Figure 5D). We also
detected the effect of palmitate on the expression of
FNDC5 at protein level. As shown, 0.4 mM and 0.6 mM
palmitate apparently reduced the protein level of FNDC5
(Figure 5E). Thus, palmitate impairs the expression of
three health benefit myokine genes but promotes the
expression of IL6 gene.
The expression of myokine genes differently responded
to pathway inhibitors
As an effort to know the potential mechanism under-
lying palmitate-altered expression of above myokines,
chemical inhibitors of PI3K and p38 were used in the
subsequent experiments. For FNDC5 gene, SB203580
significantly up-regulated the transcription of this gene
in normal myotubes, but this up-regulation was blanked
in the myotubes treated with palmitate (Figure 6A). Differ-
ently, LY294002 had no significant effect on the transcrip-
tion of FNDC5 gene in both normal and palmitate-treatedmyotubes (Figure 6B). For CTRP15 gene, either SB203580
or LY294002 altered the transcription in normal not
palmitate-treated myotubes, although the influence of
SB203580 and LY294002 in normal myotubes was oppos-
ite (Figure 6C,D). For FGF21 gene, SB203580 did not
affect the transcription in normal myotubes, but sup-
pressed that in palmitate-treated myotubes; LY294002
exerted inhibitory effect in both normal and palmitate-
treated myotubes (Figure 6E,F). Quite differently, the ef-
fect of SB203580 and LY294002 on the expression of IL6
gene was consistently negative in both normal and
palmitate-treated myotubes (Figure 6G,H). These results
demonstrate that the transcription of FNDC5, CTRP15,
FGF21 genes differently respond to SB203580 and
LY294002 in C2C12 myotubes.
Discussion
Despite many studies have reported that palmitate can
induce insulin resistance in myotubes, other phenotypes
of palmitate in myotubes were not recognized well. In
Figure 4 Palmitate-induced myotube loss associated with
protein degradation. (A) Cells were treated with 0.2 mM palmitate
for 24 hours, and BSA treatment was used as control. The
transcription of Atrogin1 and MuRF1 genes was measured by qRT-
PCR. (B) Cells were treated with palmitate for 24 hours and α-actin
and β-actin protein levels were measured by western blot. GAPDH
as control. (C) Cells were pretreated with 10 uM MG132 for 1 hour,
followed by 0.4 mM palmitate treatment for 24 hours. DMSO and
BSA treatments were used as controls for MG132 and palmitate,
respectively. Representative photographs were shown. The values
were expressed as mean±SEM (n=3).
Figure 3 Palmitate-induced myotube loss could not be
duplicated by the blockage of PI3K and p38 pathways.
Myotubes were pretreated with 10 uM LY294002, or 10 uM
SB203580 for 1 hour, followed by 0.4 mM palmitate for 24 hours.
0.1% DMSO as the control for inhibitor treatment, and BSA as the
control for palmitate treatment. (A) Representative photographs
taken under a phase contrast microscope; (B) The number of
myotubes per photograph was counted after crystal violet staining.
**p<0.01 vs. CTL. PA, palmitate; LY, LY294002; SB, SB203580.
Yang et al. Lipids in Health and Disease 2013, 12:104 Page 6 of 10
http://www.lipidworld.com/content/12/1/104the present study, we explored the connection between
palmitate treatment and two unwholesome phenomena,
myotube loss and impaired expression of health benefit
myokine genes, in C2C12 myotubes. Our results demon-
strate for the first time that palmitate-induced insulin re-
sistance in C2C12 myotubes is closely accompanied with
myotube loss and the decreased expression of three
health benefit myokine genes. These results is supportive
for the notion that excessive concentration of saturated
fatty acids in circulation is harmful for human healthy,
although we know that palmitate treatment does not
exactly fit the situation in vivo, where a mix of saturated
and unsaturated fatty acids exists. For this reason, therole of other fatty acids existing in blood is necessary to
be understand. Corresponding to the report that unsat-
urated fatty acid oleate can not stimulate insulin sensi-
tivity like palmitate [25], our result showed that oleate is
negative in the induction of myotube loss. This result is
helpful to recognize the difference between saturated
fatty acid and unsaturated fatty acid.
Skeletal muscle wasting often occurs with insulin re-
sistance [26]. For example, Wang et al. found insulin re-
sistance caused muscle wasting in db/db mice [26].
Randall et al. reported palmitate had negative effect on
the myotube size and morphology of C2C12 myotubes
Figure 5 Palmitate altered the expression of myokine genes in C2C12 myotbes. Cells were treated with palmitate for 24 hours. The
transcription of FNDC5 gene (A), CTRP15 gene (B), FGF21 gene (C) and IL6 gene (D) was measured by qRT-PCR and monitored via 18S. FNDC5
protein level was measured by western blot, GAPDH as control (E). The values were expressed as mean±SEM (n=3). *p<0.05, **p<0.01 vs. CTL.
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insulin resistance and myotube loss, we utilized C2C12
myotubes chronic exposed to palmitate as an insulin re-
sistance model. To know the mechanism underlying
palmitate-induced myotube loss, we evaluated the in-
volvement of several signaling pathways in palmitate-
induced myotube loss. Insulin/PI3K pathway is the first
one, since previous report has shown that palmitate can
suppress insulin-stimulated PI3K/Akt/mTOR pathway
[9]. However, in our system, no evidence was obtained
even a series of inhibitor-applied experiments were
conducted, since three insulin/PI3K/mTOR pathway in-
hibitors, LY294002, wortmannin, rapamycin, did not re-
sult in myotube loss like palmitate (Figure 3 and
nonpresented data) and on the other hand, two insulin/
PI3K/mTOR pathway activators, PTEN inhibitor (VO-
OHpic trihydrate) and mTOR activator (Phosphatidic
acid), did not block palmitate-induced myotube loss
(data not shown). We also concerned the involvement of
PKC pathway, because one previous view is that palmi-
tate can activate PKC in myotubes [9]. Unfortunately,
we did not successfully set up the platform for PKC
pathway inhibition experiment for practical reason.
However, our finding about the different outcomes of
palmitate and oleate on myotube loss may be a kind of
indirect evidence supportive for the involvement of PKC
in myotube loss, because it has shown that palmitate can
be metabolized into DAG, a verified intracellular PKC
activator, in myotubes, but diversely, oleate can only be
metabolized to intracellular FFAs [27]. We understandthat more direct evidence is needed to clear up the ques-
tion. For example, PKC specific inhibitor- and PKC
siRNA-involved strategise can be conducted. Actually,
we have tried the use of Staurosporine as PKC inhibitor
(data not shown). But later on, we realized that
Staurosporine is not an efficient and specific PKC inhibi-
tor. Meanwhile, we asked if p38 pathway connected to
palmitate-induced myotube loss. The result is still nega-
tive. It is worth to note here that efficiencies of the
chemical inhibitors and activators of PI3K and p38 path-
ways we used in this study have been confirmed, as they
can obviously influence the differentiation of C2C12
myoblasts (data not shown).
Palmitate-induced myotube loss is certainly connected
to protein degradation. The decline of protein level of
α-actin and β-actin we found is a confident evidence
since these two proteins are consistently expressed at
transcriptional level but eliminated at protein level. As
known, intracellular protein degradation are majorly
attributed to two mechanisms: ubiquitin proteasome
process (UPP) and lysosome-autophagy process [28].
Previous reports demonstrated that mytube loss and
muscle wasting is related to UPP [26]. In present study,
two lines of evidence are obtained. One is the decreased
level of actin proteins, and the other is the increasing
tendency of the expression of Atrogin1 and MuRF1genes,
which encode two ubiquitin E3 ligases participating in
UPP [24,26]. However, the experiment using proteasome
inhibitor MG132 needs to be further optimized, as we do
not know at this moment why the MG132 concentration
Figure 6 The transcription of myokine genes differently responded to SB203580 and LY294002. C2C12 myotubes were treated with 0.4 mM
palmitate with or without chemical inhibitors for 24 hours. The transcription of FNDC5 gene (A, B), CTRP15 gene (C, D), FGF21 gene (E, F) and IL6
gene (G, H) was measured by qRT-PCR and monitored via 18S as internal control. The values were expressed as mean±SEM (n=3). *p<0.05, **p<0.01,
ns, no significant. PA, 0.4 mM palmitate; SB, 10 uM SB203580; LY, 10 uM LY294002.
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toxic when combined with palmitate. Similar to previous
reports, up to 50 uM of MG132 was safe for the cells
when added alone [29]. For this cytotoxicity of MG132
occurring in palmitate-treated cells, one interpretation is
considerable, as it’s reported that strong proteasome mal-
function can induce severe autophagic cell death [30].
So, it is promising to detect whether palmitate-induced
myotube loss is closely related to autophagy process.Another attempt of this study is to explore the role of
palmitate in the production of several myokines. Even
preliminary, this attempt is important for enriching our
knowledge about myokine production particularly about
the influence of insulin resistance in myokine produc-
tion, which is actually a barren land up to now. Our
finding is interesting, because it shows for the first time
that palmitate-induced insulin resistant accompany with
impaired expression of three healthy benefit-oriented
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retory portion of FNDC5 protein, being able to positively
promote the browning of white adipose tissue and im-
prove insulin sensitivity in both human and mice [19];
(2) CTRP15, also known as myonectin, being able to
mediate the cross-talk between skeletal muscle and
other metabolic compartments, such as adipose tissue
and liver, to coordinate the integration of whole-body
metabolism [18]; (3) FGF21, a known endogenous regu-
lator for systemic glucose and lipid metabolism [20]. In
our study, palmitate-inhibited the expression of FNDC5
gene was evidenced at both mRNA and protein levels,
while the suppressive effect of palmitate on the expres-
sion of CTRP15 and FGF21 genes was observed only at
mRNA level because of no available antibodies. From
previous studies, a few coincidant clues can be found.
For example, high fat diet inhibited the expression of
CTRP15 gene in mice [18].
The signal pathways related to palmitate-suppressed
expression of myokine genes were briefly studied. The
results were informative but not conclusive. One valu-
able point, from our view at least, is the elimination of
the effect of SB203580 and LY294002 by palmitate. It is
that p38 inhibitor SB203580 up-regulated the transcrip-
tion of FNDC5 and CTRP15 genes in normal myotubes
but not in palmitate-treated myotubes. We consider that
two pieces of information can be extracted from these
results: the first, p38 inactivation is important for the
expression of these two genes; the second, palmitate-
suppressed expression of these two genes seems corelated
to its role in p38 activation. In fact, palmitate-induced p38
activation has got reported by others [31]. Anyway, we got
from this study that the three checked myokine genes
have their own response patterns upon pathway inhibitors,
implying the regulation mechanisms of these genes are
different. As to the transcription of FNDC5 and CTRP15
genes, p38 pathway is predominantly involved; for the
transcription of FGF21 gene expression, however, PI3K
pathway is apparent relevant.
Conclusions
In summary, palmitate-induced insulin resistance is as-
sociated with myotube loss and impaired expression of
three health benefit myokine genes (FNDC5, CTRP15
and FGF21) in C2C12 myotubes. These findings provide
new evidence for the negative impact of high concen-
tration palmitate in muscle cells. Further studies are
needed to investigate the underlying mechanism.
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